Neurology & CNS · Phase II

Top sponsors

• BRIGHT MINDS BIOSCIENCES 13 programs
• United Therapeutics Europe 12 programs
• Chinese Academy of 11 programs
• Teva Pharma 11 programs
• Jazz Pharmaceuticals Ireland 10 programs
• Acadia Pharmaceuticals 9 programs
• HOFFMANN-LA ROCHE 9 programs
• George Institute for 8 programs
• SUPERNUS PHARMACEUTICALS 8 programs
• Cognition Therapeutics 7 programs
• Takeda 7 programs
• Anaxis Pharma 6 programs

1. IM045-1018

   Celgene Europe Limited

   Multiple Sclerosis Spasticity

   phase 2 · small molecule · active

   1 trial →

2. Iloperidone

   Vanda Pharmaceuticals Netherlands B.V.

   Parkinson Disease Psychosis

   phase 2 · small molecule · terminated

   1 trial →

3. Iloperidone crystalline formulation

   Vanda Pharmaceuticals Netherlands B.V.

   Schizophrenia

   phase 2 · small molecule · completed

   1 trial →

4. Insulin

   United Therapeutics Europe Ltd

   Multiple Sclerosis, Relapsing-Remitting

   phase 2 · small molecule · completed

   1 trial →

5. K0706

   Advanced Accelerator Applications

   Early Parkinson Disease

   phase 2 · small molecule · terminated

   1 trial →

6. KYV-101

   Kyverna Therapeutics

   Multiple Sclerosis, Primary Progressive

   phase 2 · mab · active

   1 trial →

7. KYV101-007

   Kyverna Therapeutics

   Primary or Secondary Progressive Multiple Sclerosis

   phase 2 · small molecule · active

   1 trial →

8. Ketamine Hydrochloride

   BRIGHT MINDS BIOSCIENCES INC.

   Depression

   phase 2 · small molecule · completed

   1 trial →

9. LX1001

   BRIGHT MINDS BIOSCIENCES INC.

   Alzheimer Disease

   phase 2 · mab · completed

   1 trial →

10. LY2140023

    Novo Nordisk A/S

    Schizophrenia

    phase 2 · small molecule · terminated

    1 trial →

11. Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG

    MEDA Pharma GmbH & Co. KG

    Mild Cognitive impairment due to Alzheimer Disease

    phase 2 · small molecule · active

    1 trial →

12. Laquinimod 0.6

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 2 · small molecule · terminated

    1 trial →

13. Leuprolide acetate

    Voyager Therapeutics

    Alzheimer Disease

    phase 2 · small molecule · completed

    2 trials →

14. Low Dose GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 2 · small molecule · active

    1 trial →

15. Lu AA34893

    H. Lundbeck A/S

    Depression in Patients With Bipolar Disorder

    phase 2 · small molecule · terminated

    1 trial →

16. Lu AE58054

    H. Lundbeck A/S

    Schizophrenia

    phase 2 · small molecule · completed

    1 trial →

17. Luvadaxistat

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 · small molecule · completed

    2 trials →

18. MINOCIN 100 mg capsule rigide

    Zafatek

    Depression

    phase 2 · small molecule · active

    1 trial →

19. MK-1167

    Merck KGaA, Darmstadt, Germany

    Alzheimer Disease

    phase 2 · small molecule · active

    1 trial →

20. MK-1167-008

    Merck Sharp and Dohme

    Alzheimer’s disease dementia

    phase 2 · small molecule · active

    1 trial →

21. MK-2214

    Merck KGaA, Darmstadt, Germany

    Early Alzheimer's Disease

    phase 2 · mab · active

    1 trial →

22. MK-2214-004

    Merck Sharp and Dohme

    Alzheimer’s Disease

    phase 2 · small molecule · active

    1 trial →

23. ML-007C-MA

    MapLight Therapeutics

    Schizophrenia

    phase 2 · small molecule · active

    1 trial →

24. ML-007C-MA

    MapLight Therapeutics

    Psychosis Associated With Alzheimer's Disease

    phase 2 · small molecule · active

    2 trials →

25. MLC901

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 · small molecule · active

    1 trial →

26. Melperone HCl

    Lundbeck Australia Pty Ltd

    Parkinson's Disease

    phase 2 · small molecule · completed

    1 trial →

27. Mifepristone

    CORCEPT THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 · small molecule · terminated

    1 trial →

28. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 · small molecule · active

    1 trial →

29. Morphine

    Hospital Authority, Hong Kong

    Respiratory Depression

    phase 2 · small molecule · active

    1 trial →

30. N-acetyl cysteine

    United Therapeutics Europe Ltd

    Multiple Sclerosis

    phase 2 · small molecule · active

    1 trial →

31. N-acetylcysteine capsule

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 · small molecule · completed

    1 trial →

32. NBI-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 · small molecule · active

    1 trial →

33. NBI-1117570-SCZ2035

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 · small molecule · active

    1 trial →

34. NBI-5788

    NEUROCRINE BIOSCIENCES INC

    Multiple Sclerosis

    phase 2 · small molecule · completed

    1 trial →

35. NET-MS

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 · small molecule · active

    1 trial →

36. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 · small molecule · active

    2 trials →

37. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prodromal Schizophrenia

    phase 2 · small molecule · active

    1 trial →

38. NMDAE plus AIFA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 · small molecule · active

    1 trial →

39. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Treatment Resistant Depression

    phase 2 · small molecule · completed

    1 trial →

40. NeuroEPO

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson Disease

    phase 2 · small molecule · completed

    1 trial →

41. NurOwn (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Multiple Sclerosis, Chronic Progressive

    phase 2 · mab · completed

    1 trial →

42. OPC-34712

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 2 · small molecule · completed

    1 trial →

43. ORY-2001 Low dose

    BRIGHT MINDS BIOSCIENCES INC.

    Mild to Moderate Alzheimer's Disease

    phase 2 · small molecule · completed

    1 trial →

44. OXY-APS

    The George Institute

    schizophrenia or other primary psychotic disorders (SSD)

    phase 2 · small molecule · active

    1 trial →

45. Obexelimab

    Zenas BioPharma

    Relapsing Multiple Sclerosis

    phase 2 · small molecule · active

    1 trial →

46. PCN-101

    Chongqing Precision Biotech Co., Ltd

    Treatment Resistant Depression

    phase 2 · small molecule · completed

    1 trial →

47. PEG-liposomal prednisolone sodium phosphate

    Lakefront Biotherapeutics NV

    Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

    phase 2 · small molecule · terminated

    1 trial →

48. PIPE-307 Dose A

    Contineum Therapeutics

    Relapsing Remitting Multiple Sclerosis

    phase 2 · small molecule · completed

    1 trial →

Frequently asked questions